MCC950, an agent that can block NLRP3 inflammasome, decreases the expression of liver caspase-1 and the numbers of macrophages and neutrophils, ultimately alleviating liver fibrosis (Mridha et al., 2017). Here, NLRP3 is linked to Hepatic fibrosis.